{
      "Rank": 120,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Lower Dose.",
            "This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Higher Dose"
      ],
      "ArmGroupInterventionName": [
            "Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose",
            "Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose"
      ],
      "ArmGroupLabel": [
            "Lower Dose MSC",
            "Higher Dose MSC"
      ],
      "ArmGroupType": [
            "Experimental",
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT03840343"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The Researchers will assess the safety, tolerability, dosing effect, and early signals of efficacy of intra-arterially delivered autologous (from self) adipose (fat) tissue-derived mesenchymal stem/stromal cells (MSC) in patients with progressive diabetic kidney disease (DKD)."
      ],
      "BriefTitle": [
            "Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease"
      ],
      "CentralContactEMail": [
            "Lawson.Donna3@mayo.edu"
      ],
      "CentralContactName": [
            "Donna Lawson"
      ],
      "CentralContactPhone": [
            "507-255-7975"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact"
      ],
      "CollaboratorClass": [
            "UNKNOWN"
      ],
      "CollaboratorName": [
            "Regenerative Medicine Minnesota"
      ],
      "CompletionDate": [
            "December 2025"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Diabetic Kidney Disease",
            "Diabetic Nephropathies",
            "Diabetes Mellitus, Type 2",
            "Diabetes Mellitus, Type 1",
            "Chronic Kidney Disease",
            "Diabetic Nephropathy Type 2",
            "Kidney Failure",
            "Kidney Insufficiency"
      ],
      "ConditionAncestorId": [
            "D000044882",
            "D000008659",
            "D000004700",
            "D000014570",
            "D000001327",
            "D000007154",
            "D000048909"
      ],
      "ConditionAncestorTerm": [
            "Glucose Metabolism Disorders",
            "Metabolic Diseases",
            "Endocrine System Diseases",
            "Urologic Diseases",
            "Autoimmune Diseases",
            "Immune System Diseases",
            "Diabetes Complications"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC18",
            "BC19",
            "All",
            "BXS",
            "BC20",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Nutritional and Metabolic Diseases",
            "Gland and Hormone Related Diseases",
            "All Conditions",
            "Urinary Tract, Sexual Organs, and Pregnancy Conditions",
            "Immune System Diseases",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Diabetes Mellitus",
            "Kidney Disease",
            "Diabetes Mellitus, Type 2",
            "Diabetes Mellitus, Type 1",
            "Kidney Insufficiency",
            "Diabetic Nephropathy",
            "Chronic Kidney Disease"
      ],
      "ConditionBrowseLeafId": [
            "M6267",
            "M9850",
            "M6271",
            "M6269",
            "M25871",
            "M6275",
            "M25870",
            "M10791",
            "M24556",
            "M7014",
            "M16471",
            "M3781",
            "M9352",
            "M25157",
            "T1303"
      ],
      "ConditionBrowseLeafName": [
            "Diabetes Mellitus",
            "Kidney Diseases",
            "Diabetes Mellitus, Type 2",
            "Diabetes Mellitus, Type 1",
            "Renal Insufficiency",
            "Diabetic Nephropathies",
            "Renal Insufficiency, Chronic",
            "Metabolic Diseases",
            "Glucose Metabolism Disorders",
            "Endocrine System Diseases",
            "Urologic Diseases",
            "Autoimmune Diseases",
            "Immune System Diseases",
            "Diabetes Complications",
            "Chronic Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "high",
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000007674",
            "D000051436",
            "D000051437",
            "D000003928",
            "D000003920",
            "D000003924",
            "D000003922"
      ],
      "ConditionMeshTerm": [
            "Kidney Diseases",
            "Renal Insufficiency, Chronic",
            "Renal Insufficiency",
            "Diabetic Nephropathies",
            "Diabetes Mellitus",
            "Diabetes Mellitus, Type 2",
            "Diabetes Mellitus, Type 1"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Non-Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "This is a single center, open-label dose-escalating study assessing safety, tolerability, dosing effect, and early signals of efficacy of intra-arterially delivered autologous (from self) adipose tissue-derived mesenchymal stem/stromal cells (MSC) in 30 patients with progressive diabetic kidney disease (DKD). DKD will be defined as chronic kidney disease (CKD; estimated glomerular filtration rate; eGFR<60 mL/min/1.73m2) in the setting of diabetes mellitus (type 2; on anti-diabetes therapy) without overt etiologies of CKD beyond concomitant hypertension. Progressive DKD will be considered as eGFR 25-55 ml/min/1.73m2 with a) eGFR decline of 5 ml/min over 18 months or 10 ml/min over 3 years or b) an intermediate or high 5-year risk of progression to end-stage kidney failure (dialysis or transplant) based on the validated Tangri 4-variable (age, sex, eGFR, urinary albumin-creatinine ratio) kidney failure risk equation. Fifteen subjects will be placed in one of two cell dosage arms in a parallel design with single-kidney MSC administration at Day 0 and Month 3. Subjects will be followed a total of 15 months from time of initial cell administration."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nDiabetes mellitus (on anti-diabetes drug therapy)\nAge 45-75 years\neGFR 25-55 ml/min/1.73m2 at time of consent with: a) eGFR decline of 5 ml/min over 18 months or 10 ml/min over 3 years or b) an intermediate or high 5-year risk of progression to end-stage kidney failure (dialysis or transplant) based on the validated Tangri 4-variable (age, sex, eGFR, urinary albumin-creatinine ratio) kidney failure risk equation https://kidneyfailurerisk.com/\nPrimary cause of kidney disease is diabetes without suspicion of concomitant kidney disease beyond hypertension\nSpot urine albumin:creatinine \u226530 mg/g unless on RAAS inhibition\nAbility to give informed consent\n\nExclusion Criteria:\n\nHemoglobin A1c\u226511%\nPregnancy\nActive malignancy\nActive Immunosuppression therapy\nKidney transplantation history\nConcomitant glomerulonephritis\nNephrotic syndrome\nSolid organ transplantation history\nAutosomal dominant or recessive polycystic kidney disease\nKnown renovascular disease\nKidney failure (hemodialysis, peritoneal dialysis, or kidney transplantation)\nActive tobacco use\nBody weight >150 kg or BMI>50\nUncontrolled hypertension: Systolic blood pressure (SBP) >180 mmHg despite antihypertensive therapy\nRecent cardiovascular event (myocardial infarction, stroke, congestive heart failure within 6 months\nEvidence of hepatitis B or C, or HIV infection, chronic\nAnticoagulation therapy requiring heparin bridging for procedures.\nHistory of methicillin-resistant staphylococcus aureus colonization\nRecent plastic, chemical or surgical manipulation of adipose tissue for cosmetic purposes within 6 months\nInability to give informed consent\nPotentially unreliable subjects and those judged by the investigator to be unsuitable for the study"
      ],
      "EnrollmentCount": [
            "30"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Lower Dose MSC",
            "Higher Dose MSC"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "Two MSC infusions of 2.5x10^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery",
            "Two MSC infusions of 5.0x10^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose",
            "Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Biological"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "Yes"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Mesenchymal Stem Cell",
            "Mesencymal Stromal Cell",
            "Stem Cell",
            "Regenerative Medicine",
            "Cell therapy",
            "Rejuvenation"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "March 15, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "March 11, 2022"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Mayo Clinic"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Rochester"
      ],
      "LocationContactEMail": [
            "Lawson.Donna3@mayo.edu"
      ],
      "LocationContactName": [
            "Donna Lawson",
            "LaTonya J Hickson, MD"
      ],
      "LocationContactPhone": [
            "507-255-7975"
      ],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact",
            "Principal Investigator"
      ],
      "LocationCountry": [
            "United States"
      ],
      "LocationFacility": [
            "Mayo Clinic in Rochester"
      ],
      "LocationState": [
            "Minnesota"
      ],
      "LocationStatus": [
            "Recruiting"
      ],
      "LocationZip": [
            "55905"
      ],
      "MaximumAge": [
            "75 Years"
      ],
      "MinimumAge": [
            "45 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Intra-arterially Delivered Autologous Mesenchymal Stem/Stromal Cell Therapy in Patients With Diabetic Kidney Disease: A Phase I Study"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Mayo Clinic"
      ],
      "OrgStudyId": [
            "18-002423"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Mayo Clinic"
      ],
      "OverallOfficialName": [
            "LaTonya J Hickson, MD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Recruiting"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 2024"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "The number of Adverse Events associated with MSC intervention per treatment arm",
            "The percentage of Adverse Events associated with MSC intervention per treatment arm"
      ],
      "PrimaryOutcomeMeasure": [
            "Adverse Events",
            "Adverse Events"
      ],
      "PrimaryOutcomeTimeFrame": [
            "Baseline through Month 15",
            "Baseline through Month 15"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "Mayo Clinic"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "LaTonya J. Hickson"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Principal Investigator"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Principal Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [
            "RMM 091718 CT 001"
      ],
      "SecondaryIdDomain": [
            "Regenerative Medicine Minnesota"
      ],
      "SecondaryIdLink": [],
      "SecondaryIdType": [
            "Other Grant/Funding Number"
      ],
      "SecondaryOutcomeDescription": [
            "Change in measured glomerular filtration rate (mGFR). Measured as mL/min/BSA",
            "Change in estimated glomerular filtration rate (eGFR) slope. Measured as mL/min/1.73m^2/month"
      ],
      "SecondaryOutcomeMeasure": [
            "Kidney Function",
            "Kidney Function"
      ],
      "SecondaryOutcomeTimeFrame": [
            "baseline, month 6",
            "pretreatment, month 12"
      ],
      "SeeAlsoLinkLabel": [
            "Diabetic Kidney Disease Stem Cell Trial - Mayo Clinic",
            "Stem Cells and Kidney Disease - Mayo Clinic",
            "Video of Stem Cell Trial in Diabetic Kidney Disease - Regenerative Medicine Minnesota"
      ],
      "SeeAlsoLinkURL": [
            "https://www.mayo.edu/research/clinical-trials/cls-20438442",
            "https://regenerativemedicineblog.mayoclinic.org/2018/10/26/stem-cells-and-chronic-kidney-disease/",
            "https://youtu.be/DQ7r3UFMDN8"
      ],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "October 23, 2019"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "March 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "February 15, 2019"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "February 11, 2019"
      ],
      "StudyFirstSubmitQCDate": [
            "February 11, 2019"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}